Pressure Bio Stock Price, News & Analysis

Pressure BioSciences, Inc. (OTCQB:PBIO) has entered a manufacturing and distribution agreement with CBD Supply MD, projected to generate over $1.5 million in revenue during 2023. The deal involves supplying UltraShear™ optimized nanoemulsified CBD products, starting with an initial shipment of 850 vials by mid-April 2023. This collaboration aims to enhance product effectiveness with rapid absorption and high potency. Executives from both companies expressed confidence in the partnership's potential, highlighting the advanced technology's unique benefits and market needs. PBIO is also planning to uplist to NASDAQ or NYSE later in the year.

Pressure BioSciences (OTCQB:PBIO) announced a significant equity exchange where its largest investor converted over $10 million in senior secured debt into unsecured preferred stock. This exchange, valued at $2.50 per share, represents more than 50% of the total debt owed to this investor and around 30% of PBIO's overall debt. The company noted recent advancements in its Ultra Shear Technology, enhancing products in cosmeceuticals and sports recovery sectors. CEO Richard T. Schumacher expressed optimism about the company's future and the potential for further debt-to-equity conversions from other investors.

Pressure BioSciences, Inc. (OTCQB:PBIO) announced a significant milestone with a prepaid order from PRS International Trade for 16 Barocycler EXT units totaling nearly $600,000. This marks the largest single order in the company's history, reflecting strong demand for its Pressure Cycling Technology (PCT) products. The company expects this order will contribute to a robust first quarter in 2023, alongside increasing global sales for its pressure-based instruments and its new UltraShear nanoemulsions platform. CEO Richard T. Schumacher emphasized the potential for substantial revenue growth this year as the company expands its market reach into China and other regions.

Pressure BioSciences, Inc. (OTCQB: PBIO) has partnered with One World Products, Inc. (OTCQB: OWPC) to innovate a new line of CBD-infused sports performance and recovery drinks. This collaboration aims to utilize PBIO's UltraShear nanoemulsification technology to enhance the bioavailability of CBD and improve recovery times for athletes. The sports performance drink market was valued at approximately $9.5 billion in 2021. The venture targets both athletes and non-athletes, leveraging trends in health and wellness. The partnership is positioned to offer competitive advantage over existing products by enabling faster absorption of ingredients.

Pressure BioSciences, Inc. (OTCQB:PBIO) announced positive results from consumer testing of its THC Nanoemulsion Oral Spray, developed using its Ultra Shear Technology (UST). The spray demonstrated quick onset, with effects noted as soon as 1-10 minutes and peaks within 15-60 minutes, addressing issues with traditional THC edibles that delay effects. The product aims to disrupt the cannabis market by offering reliable dosing without respiratory risks associated with smoking or vaping. PBI anticipates significant revenue from its California partners as they prepare for product launch this quarter.

Pressure BioSciences, Inc. (PBIO) anticipates significant revenue growth in 2023, driven by its newly launched Ultra Shear Technology™ (UST). The company predicts Q4 2022 revenue to be the highest in four years and expects continuous quarter-over-quarter growth in 2023. Key agreements including four executed that could yield over $1M annually each, alongside anticipated strong performance in UltraShear Nano-CBD and other products, are set to enhance profitability. Management aims for breakeven by the end of the year and plans to uplist to a national exchange.

Pressure BioSciences, Inc. (OTCQB:PBIO) announced the receipt of a $75,000 payment for the first commercial lot of a CBD oral spray developed with its Ultra Shear Technology™. This product is part of a multi-year agreement with Safer Medical of Montana, targeting rapid absorption and high potency for the U.S. veterans community. The company expects revenues exceeding $1 million in Q1/Q2 2023 from subsequent phases of this agreement, emphasizing significant growth potential in various sectors, including pharmaceuticals and nutraceuticals.

Pressure BioSciences, Inc. (OTCQB:PBIO) announced that their collaboration with renowned skincare expert Dr. Adrienne Denese has achieved exceptional results in developing next-gen skincare products. Utilizing their patented Ultra Shear Technology™, PBI has successfully nanoemulsified retinoate and Vitamin C, aiming to enhance bioavailability in Dr. Denese's anti-aging products. Dr. Denese reported unprecedented skin tightening effects and plans to advance the serum into clinical trials. PBI anticipates commercial sales of these products could begin in Q2 2023, leading to significant revenue growth.

Pressure BioSciences (OTCQB:PBIO) reported Q3 2022 total revenue of $144,000, a 72% decline from $518,000 in Q3 2021. Instrument sales fell 66% to $134,000, while agrochem sales dropped 41% to $10,000. Operating loss increased by 10% to $1,363,000. Despite these challenges, the company anticipates a strong Q4, driven by their Ultra Shear Technology (UST) commercialization efforts. Key partnerships and product launches are set for 2023, with projected profitability expected by year-end. Investor call scheduled for November 22, 2022.